Envestnet Asset Management Inc. trimmed its position in Glaukos Co. (NYSE:GKOS – Get Rating) by 11.7% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 45,250 shares of the medical instruments supplier’s stock after selling 5,987 shares during the period. Envestnet Asset Management Inc. owned about 0.10% of Glaukos worth $2,055,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in GKOS. Captrust Financial Advisors grew its position in shares of Glaukos by 119.5% during the 1st quarter. Captrust Financial Advisors now owns 1,484 shares of the medical instruments supplier’s stock valued at $86,000 after acquiring an additional 808 shares during the period. Hardy Reed LLC bought a new position in shares of Glaukos during the 1st quarter valued at approximately $90,000. Nisa Investment Advisors LLC grew its position in shares of Glaukos by 16.1% during the 1st quarter. Nisa Investment Advisors LLC now owns 3,170 shares of the medical instruments supplier’s stock valued at $183,000 after acquiring an additional 440 shares during the period. HighTower Advisors LLC bought a new position in shares of Glaukos during the 1st quarter valued at approximately $208,000. Finally, Quantum Private Wealth LLC bought a new position in shares of Glaukos during the 1st quarter valued at approximately $222,000. 93.09% of the stock is owned by institutional investors.
Glaukos Stock Performance
Glaukos stock opened at $48.88 on Friday. The firm’s fifty day moving average price is $53.42 and its 200-day moving average price is $49.09. The company has a debt-to-equity ratio of 0.64, a quick ratio of 6.84 and a current ratio of 7.40. The stock has a market cap of $2.33 billion, a P/E ratio of -25.73 and a beta of 1.26. Glaukos Co. has a fifty-two week low of $33.33 and a fifty-two week high of $64.49.
Wall Street Analysts Forecast Growth
Several research firms recently commented on GKOS. JPMorgan Chase & Co. cut their price objective on shares of Glaukos from $52.00 to $48.00 and set an “underweight” rating for the company in a report on Thursday, November 3rd. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a report on Thursday, November 3rd. Needham & Company LLC cut their price objective on shares of Glaukos from $66.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, November 3rd. Stephens began coverage on shares of Glaukos in a report on Thursday, October 13th. They issued an “overweight” rating and a $69.00 price objective for the company. Finally, Citigroup raised their price objective on shares of Glaukos from $54.00 to $57.00 in a report on Wednesday, October 5th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Glaukos has a consensus rating of “Hold” and an average target price of $60.13.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
- Get a free copy of the StockNews.com research report on Glaukos (GKOS)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.